Phage display as a promising approach for vaccine development

Journal of Biomedical Science

Volumn 23, Issue 1, 2016, Pages

  Aghebati Maleki, Leili ^a,b,c   Bakhshinejad, Babak ^d   Baradaran, Behzad ^a,c   Motallebnezhad, Morteza ^a   Aghebati Maleki, Ali ^a   Nickho, Hamid ^a   Yousefi, Mehdi ^b,c   Majidi, Jafar ^a,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Bacteriophage; Biopanning; Mimotope; Peptide library; Phage display; Vaccine development

Indexed keywords

ANTIBODY; CYTOKINE; EPITOPE; PEPTIDE DERIVATIVE; VACCINE;

ADAPTIVE IMMUNITY; BACTERIOPHAGE; BIOPANNING; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 84989306634     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-016-0285-9     Document Type: Review

References (149)

1. Douglas T, Young M. Viruses: making friends with old foes. Science. 2006;312(5775):873-5.
2. Babel I, Barderas R, Diaz-Uriarte R, Moreno V, Suarez A, Fernandez-Acenero MJ, Salazar R, Capella G, Casal JI. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics. 2011;10(3):M110 001784.
3. Mokili JL, Rohwer F, Dutilh BE. Metagenomics and future perspectives in virus discovery. Curr Opin Virol. 2012;2(1):63-77.
4. Rohwer F, Segall AM. In retrospect: A century of phage lessons. Nature. 2015;528(7580):46-8.
5. Sundell GN, Ivarsson Y. Interaction analysis through proteomic phage display. Biomed Res Int. 2014;2014:176172.
6. Castel G, Chteoui M, Heyd B, Tordo N. Phage display of combinatorial peptide libraries: application to antiviral research. Molecules. 2011;16(5):3499-518.
7. Bakhshinejad B, Sadeghizadeh M. Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection. World J Gastroenterol. 2014;20(33):11671-83.
8. Budynek P, Dabrowska K, Skaradzinski G, Gorski A. Bacteriophages and cancer. Arch Microbiol. 2010;192(5):315-20.
9. Schmelcher M, Loessner MJ. Application of bacteriophages for detection of foodborne pathogens. Bacteriophage. 2014;4(1):e28137.
10. Tawil N, Sacher E, Mandeville R, Meunier M. Bacteriophages: biosensing tools for multi-drug resistant pathogens. Analyst. 2014;139(6):1224-36.
11. Bedi D, Gillespie JW, Petrenko Jr VA, Ebner A, Leitner M, Hinterdorfer P, Petrenko VA. Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol Pharm. 2013;10(2):551-9.
12. Bakhshinejad B, Sadeghizadeh M. Bacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems. Expert Opin Drug Deliv. 2014;11(10):1561-74.
13. Bakhshinejad B, Karimi M, Khalaj-Kondori M. Phage display: development of nanocarriers for targeted drug delivery to the brain. Neural Regen Res. 2015;10(6):862-5.
14. van Kan-Davelaar HE, van Hest JC, Cornelissen JJ, Koay MS. Using viruses as nanomedicines. Br J Pharmacol. 2014;171(17):4001-9.
15. Farr R, Choi DS, Lee SW. Phage-based nanomaterials for biomedical applications. Acta Biomater. 2014;10(4):1741-50.
16. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705):1315-7.
17. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993;217:228-57.
18. Noren KA, Noren CJ. Construction of high-complexity combinatorial phage display peptide libraries. Methods. 2001;23(2):169-78.
19. Babickova J, Tothova L, Boor P, Celec P. In vivo phage display - a discovery tool in molecular biomedicine. Biotechnol Adv. 2013;31(8):1247-59.
20. Matthews LJ, Davis R, Smith GP. Immunogenically fit subunit vaccine components via epitope discovery from natural peptide libraries. J Immunol. 2002;169(2):837-46.
21. Mullen LM, Nair SP, Ward JM, Rycroft AN, Henderson B. Phage display in the study of infectious diseases. Trends Microbiol. 2006;14(3):141-7.
22. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 1996;2(3):299-305.
23. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380(6572):364-6.
24. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv. 2010;28(6):849-58.
25. Konthur Z, Wilde J, Lim TS. Semi-automated Magnetic Bead-Based Antibody Selection from Phage Display Libraries. In: Antibody Engineering. Vol. 1. Kontermann R and Dübel S, editors. Springer-Verlag Berlin: Heidelberg; 2010. doi: 10.1007/978-3-642-01144-3-18.
26. Ahmed S, Mathews AS, Byeon N, Lavasanifar A, Kaur K. Peptide arrays for screening cancer specific peptides. Anal Chem. 2010;82(18):7533-41.
27. New England BioLabs, Ph.D.™-7 Phage Display Peptide Library Instruction Manual https://www.neb.com/products/e8102-phd-7-phage-display-peptide-library.
28. Murai R, Nogi T, Tateoka K, Sato A. Affinity Selection of Peptide Binders with Magnetic Beads via Organic Phase Separation (MOPS). Biol Pharm Bull. 2015;38(11):1822-6.
29. Lee L, Buckley C, Blades MC, Panayi G, George AJ, Pitzalis C. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum. 2002;46(8):2109-20.
30. Ludtke JJ, Sololoff AV, Wong SC, Zhang G, Wolff JA. In vivo selection and validation of liver-specific ligands using a new T7 phage peptide display system. Drug Deliv. 2007;14(6):357-69.
31. Rivinoja A, Laakkonen P. Identification of homing peptides using the in vivo phage display technology. Methods Mol Biol. 2011;683:401-15.
32. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377-80.
33. Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, Weaver DL, Burdette-Radoux S, Thomas C. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 2006;66(15):7724-33.
34. Laakkonen P, Zhang L, Ruoslahti E. Peptide targeting of tumor lymph vessels. Ann N Y Acad Sci. 2008;1131:37-43.
35. Clementi N, Mancini N, Solforosi L, Castelli M, Clementi M, Burioni R. Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int J Mol Sci. 2012;13(7):8273-92.
36. Zhao A, Tohidkia MR, Siegel DL, Coukos G, Omidi Y. Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Crit Rev Biotechnol. 2016;36(2):276-89.
37. Schirrmann T, Meyer T, Schutte M, Frenzel A, Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules. 2011;16(1):412-26.
38. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A, Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296(1):57-86.
39. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446-8.
40. Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PM. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond). 2015;10(1):161-74.
41. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775-97.
42. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem. 2004;279(2):1256-61.
43. Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. 2006;12(5):580-4.
44. Dolk E, van der Vaart M, Lutje Hulsik D, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol. 2005;71(1):442-50.
45. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrips CT, Hammarstrom L, van Klinken BJ. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine. 2006;24(19):4130-7.
46. El Khattabi M, Adams H, Heezius E, Hermans P, Detmers F, Maassen B, van der Ley P, Tommassen J, Verrips T, Stam J. Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications. Clin Vaccine Immunol. 2006;13(10):1079-86.
47. Goldman ER, Anderson GP, Liu JL, Delehanty JB, Sherwood LJ, Osborn LE, Cummins LB, Hayhurst A. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem. 2006;78(24):8245-55.
48. Goldman ER, Anderson GP, Conway J, Sherwood LJ, Fech M, Vo B, Liu JL, Hayhurst A. Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex. Anal Chem. 2008;80(22):8583-91.
49. Adams H, Brummelhuis W, Maassen B, van Egmond N, El Khattabi M, Detmers F, Hermans P, Braam B, Stam J, Verrips T. Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma. Biotechnol Bioeng. 2009;104(1):143-51.
50. Mazumdar S. Raxibacumab. MAbs. 2009;1(6):531-8.
51. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, Buckingham S, Vernacchio L, Ambrosino DM. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178(6):1555-61.
52. de la Cruz VF, Lal AA, McCutchan TF. Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J Biol Chem. 1988;263(9):4318-22.
53. Merril CR, Geier MR, Petricciani JC. Bacterial virus gene expression in human cells. Nature. 1971;233(5319):398-400.
54. Adhya S, Merril CR, Biswas B. Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harb Perspect Med. 2014;4(1):a012518.
55. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005;49(7):2874-8.
56. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A. 2002;99(3):1527-31.
57. van Houten NE, Henry KA, Smith GP, Scott JK. Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine. 2010;28(10):2174-85.
58. van Houten NE, Zwick MB, Menendez A, Scott JK. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine. 2006;24(19):4188-200.
59. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546-9.
60. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005;11(1):361-9.
61. Gaubin M, Fanutti C, Mishal Z, Durrbach A, De Berardinis P, Sartorius R, Del Pozzo G, Guardiola J, Perham RN, Piatier-Tonneau D. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol. 2003;22(1):11-8.
62. Bazan J, Calkosinski I, Gamian A. Phage display - a powerful technique for immunotherapy: 2. Vaccine delivery. Hum Vaccin Immunother. 2012;8(12):1829-35.
63. Delmastro P, Meola A, Monaci P, Cortese R, Galfre G. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine. 1997;15(11):1276-85.
64. Zuercher AW, Miescher SM, Vogel M, Rudolf MP, Stadler MB, Stadler BM. Oral anti-IgE immunization with epitope-displaying phage. Eur J Immunol. 2000;30(1):128-35.
65. Ren ZJ, Tian CJ, Zhu QS, Zhao MY, Xin AG, Nie WX, Ling SR, Zhu MW, Wu JY, Lan HY, Cao YC, Bi YZ. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100 % protection from potency challenge in mice. Vaccine. 2008;26(11):1471-81.
66. Kamme C. Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections. Acta Pathol Microbiol Scand B Microbiol Immunol. 1973;81(6):741-8.
67. Gorski A, Weber-Dabrowska B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci. 2005;62(5):511-9.
68. Gorski A, Miedzybrodzki R, Borysowski J, Dabrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Lusiak-Szelachowska M, Klak M, Jonczyk E, Kaniuga E, Golas A, Purchla S, Weber-Dabrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawelczyk Z, Rogoz P, Klosowska D. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res. 2012;83:41-71.
69. Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov. 2003;2(6):489-97.
70. Srivastava AS, Kaido T, Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods. 2004;115(1):99-104.
71. Greenwood J, Willis AE, Perham RN. Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens. J Mol Biol. 1991;220(4):821-7.
72. di Marzo VF, Willis AE, Boyer-Thompson C, Appella E, Perham RN. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120. J Mol Biol. 1994;243(2):167-72.
73. De Berardinis P, D'Apice L, Prisco A, Ombra MN, Barba P, Del Pozzo G, Petukhov S, Malik P, Perham RN, Guardiola J. Recognition of HIV-derived B and T cell epitopes displayed on filamentous phages. Vaccine. 1999;17(11-12):1434-41.
74. Bastien N, Trudel M, Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology. 1997;234(1):118-22.
75. Sartorius R, Pisu P, D'Apice L, Pizzella L, Romano C, Cortese G, Giorgini A, Santoni A, Velotti F, De Berardinis P. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. J Immunol. 2008;180(6):3719-28.
76. De Berardinis P, Sartorius R, Fanutti C, Perham RN, Del Pozzo G, Guardiola J. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat Biotechnol. 2000;18(8):873-6.
77. Diacovich L, Gorvel JP. Bacterial manipulation of innate immunity to promote infection. Nat Rev Microbiol. 2010;8(2):117-28.
78. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-45.
79. Kurzepa A, Dabrowska K, Skaradzinski G, Gorski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med. 2009;9(2):93-100.
80. Zimecki M, Artym J, Kocieba M, Weber-Dabrowska B, Borysowski J, Gorski A. Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. BMC Microbiol. 2009;9:169.
81. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother. 2011;55(4):1358-65.
82. Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000;121(2):87-97.
83. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol. 2004;5(10):981-6.
84. Clark JR, March JB. Bacterial viruses as human vaccines? Expert Rev Vaccines. 2004;3(4):463-76.
85. Clark JR, March JB. Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol Med Microbiol. 2004;40(1):21-6.
86. March JB, Clark JR, Jepson CD. Genetic immunisation against hepatitis B using whole bacteriophage lambda particles. Vaccine. 2004;22(13-14):1666-71.
87. Kobayashi N, Oyama H, Nakano M, Kanda T, Banzono E, Kato Y, Karibe T, Nishio T, Goto J. "Cleavable" hapten-biotin conjugates: preparation and use for the generation of anti-steroid single-domain antibody fragments. Anal Biochem. 2009;387(2):257-66.
88. Rakonjac J, Bennett NJ, Spagnuolo J, Gagic D, Russel M. Filamentous bacteriophage: biology, phage display and nanotechnology applications. Curr Issues Mol Biol. 2011;13(2):51-76.
89. Hayes S, Gamage LN, Hayes C. Dual expression system for assembling phage lambda display particle (LDP) vaccine to porcine Circovirus 2 (PCV2). Vaccine. 2010;28(41):6789-99.
90. Li Q, Shivachandra SB, Leppla SH, Rao VB. Bacteriophage T4 capsid: a unique platform for efficient surface assembly of macromolecular complexes. J Mol Biol. 2006;363(2):577-88.
91. Li XH, Tang L, Liu D, Sun HM, Zhou CC, Tan LS, Wang LP, Zhang PD, Zhang SQ. Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng. 2006;25(10):1221-6.
92. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Muller P, Bachmann MF. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031-40.
93. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, Bangala Y, Guessous I, Muller P, Willers J, Maurer P, Bachmann MF, Cerny T. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3(6):e2547.
94. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, Do Carmo Caldeira J, Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol. 2008;380(1):252-63.
95. Melzer H, Baier K, Felici F, von Specht BU, Wiedermann G, Kollaritsch H, Wiedermann U, Duchene M. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol Med Microbiol. 2003;37(2-3):179-83.
96. Su QP, Wen DZ, Yang Q, Zhang YH, Liu C, Wang L. Comparison of phage pVIII and KLH as vector in inducing the production of cytokines in C57BL/6 J mice. Vaccine. 2007;25(6):970-5.
97. Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol. 2001;5(3):314-24.
98. Meola A, Delmastro P, Monaci P, Luzzago A, Nicosia A, Felici F, Cortese R, Galfre G. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J Immunol. 1995;154(7):3162-72.
99. Goulart LR, Santos PS. Strategies for Vaccine Design Using Phage Display-Derived Peptides. Methods Mol Biol. 2016;1404:423-35.
100. Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines. 2011;10(3):299-306.
101. Costa LE, Goulart LR, Pereira NC, Lima MI, Duarte MC, Martins VT, Lage PS, Menezes-Souza D, Ribeiro TG, Melo MN, Fernandes AP, Soto M, Tavares CA, Chavez-Fumagalli MA, Coelho EA. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis. PLoS One. 2014;9(10):e110014.
102. Grothaus MC, Srivastava N, Smithson SL, Kieber-Emmons T, Williams DB, Carlone GM, Westerink MA. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine. 2000;18(13):1253-63.
103. Park I, Choi IH, Kim SJ, Shin JS. Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide. Yonsei Med J. 2004;45(4):755-8.
104. Prinz DM, Smithson SL, Westerink MA. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C. J Immunol Methods. 2004;285(1):1-14.
105. Scala G, Chen X, Liu W, Telles JN, Cohen OJ, Vaccarezza M, Igarashi T, Fauci AS. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol. 1999;162(10):6155-61.
106. Folgori A, Tafi R, Meola A, Felici F, Galfre G, Cortese R, Monaci P, Nicosia A. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J. 1994;13(9):2236-43.
107. Beckmann C, Brittnacher M, Ernst R, Mayer-Hamblett N, Miller SI, Burns JL. Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections. Infect Immun. 2005;73(1):444-52.
108. Gnanasekar M, Rao KV, He YX, Mishra PK, Nutman TB, Kaliraj P, Ramaswamy K. Novel phage display-based subtractive screening to identify vaccine candidates of Brugia malayi. Infect Immun. 2004;72(8):4707-15.
109. Santos PS, Nascimento R, Rodrigues LP, Santos FA, Faria PC, Martins JR, Brito-Madurro AG, Madurro JM, Goulart LR. Functional epitope core motif of the Anaplasma marginale major surface protein 1a and its incorporation onto bioelectrodes for antibody detection. PLoS One. 2012;7(3):e33045.
110. Wang H, Gao Y, Gong Y, Chen X, Liu C, Zhou X, Blackall PJ, Zhang P, Yang H. Identification and immunogenicity of an immunodominant mimotope of Avibacterium paragallinarum from a phage display peptide library. Vet Microbiol. 2007;119(2-4):231-9.
111. Mertens P, Walgraffe D, Laurent T, Deschrevel N, Letesson JJ, De Bolle X. Selection of phage-displayed peptides recognised by monoclonal antibodies directed against the lipopolysaccharide of Brucella. Int Rev Immunol. 2001;20(2):181-99.
112. Melzer H, Fortugno P, Mansouri E, Felici F, Marinets A, Wiedermann G, Kollaritsch H, Von Specht BU, Duchene M. Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of Entamoeba histolytica. Parasite Immunol. 2002;24(6):321-8.
113. Villa-Mancera A, Quiroz-Romero H, Correa D, Ibarra F, Reyes-Perez M, Reyes-Vivas H, Lopez-Velazquez G, Gazarian K, Gazarian T, Alonso RA. Induction of immunity in sheep to Fasciola hepatica with mimotopes of cathepsin L selected from a phage display library. Parasitology. 2008;135(12):1437-45.
114. Larralde OG, Martinez R, Camacho F, Amin N, Aguilar A, Talavera A, Stott DI, Perez EM. Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity. J Virol Methods. 2007;140(1-2):49-58.
115. Zhang WY, Wan Y, Li DG, Tang Y, Zhou W. A mimotope of pre-S2 region of surface antigen of viral hepatitis B screened by phage display. Cell Res. 2001;11(3):203-8.
116. El-Attar LM, Partidos CD, Howard CR. A peptide mimotope of hepatitis C virus E2 protein is immunogenic in mice and block human anti-HCV sera. J Med Virol. 2010;82(10):1655-65.
117. Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology. 2000;269(1):47-53.
118. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, Cohen OJ, Van Cott TC, Iwanicki M, Lewis MG, Greenhouse J, Barry T, Venzon D, Fauci AS. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med. 2001;7(11):1225-31.
119. Shcherbakova NS, Shcherbakov DN, Bakulina AY, Karpenko LI, Ryzhikov AB, Ilyichev AA. Artificial polyepitope HIV-1 immunogen containing mimotope of 2 F5 epitope. Protein Pept Lett. 2016;23(2):159-68.
120. Becker M, Felsberger A, Frenzel A, Shattuck WM, Dyer M, Kugler J, Zantow J, Mather TN, Hust M. Application of M13 phage display for identifying immunogenic proteins from tick (Ixodes scapularis) saliva. BMC Biotechnol. 2015;15:43.
121. Lin CW, Wu SC. Identification of mimotopes of the Japanese encephalitis virus envelope protein using phage-displayed combinatorial peptide library. J Mol Microbiol Biotechnol. 2004;8(1):34-42.
122. Costa LE, Lima MI, Chavez-Fumagalli MA, Menezes-Souza D, Martins VT, Duarte MC, Lage PS, Lopes EG, Lage DP, Ribeiro TG, Andrade PH, de Magalhaes-Soares DF, Soto M, Tavares CA, Goulart LR, Coelho EA. Subtractive phage display selection from canine visceral leishmaniasis identifies novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications. Clin Vaccine Immunol. 2014;21(1):96-106.
123. Toledo-Machado CM, Bueno LL, Menezes-Souza D, Machado-de-Avila RA, Nguyen C, Granier C, Bartholomeu DC, Chavez-Olortegui C, Fujiwara RT. Use of Phage Display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes. Parasit Vectors. 2015;8:133.
124. Costa LE, Chavez-Fumagalli MA, Martins VT, Duarte MC, Lage DP, Lima MI, Pereira NC, Soto M, Tavares CA, Goulart LR, Coelho EA. Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection. Parasitology. 2015;142(10):1335-47.
125. Rhaiem RB, Houimel M. Targeting Leishmania major parasite with peptides derived from a combinatorial phage display library. Acta Trop. 2016;159:11-9.
126. Ramasoota P, Tungtrakanpoung R, Pitaksajjakul P, Ekpo P, Froman G, Chaicumpa W. Epitope mapping of monoclonal antibodies specific to serovar of Leptospira, using phage display technique. Southeast Asian J Trop Med Public Health. 2005;36 Suppl 4:206-12.
127. Yang WJ, Lai JF, Peng KC, Chiang HJ, Weng CN, Shiuan D. Epitope mapping of Mycoplasma hyopneumoniae using phage displayed peptide libraries and the immune responses of the selected phagotopes. J Immunol Methods. 2005;304(1-2):15-29.
128. Eshaghi M, Tan WS, Yusoff K. Identification of epitopes in the nucleocapsid protein of Nipah virus using a linear phage-displayed random peptide library. J Med Virol. 2005;75(1):147-52.
129. Adda CG, Tilley L, Anders RF, Foley M. Isolation of peptides that mimic epitopes on a malarial antigen from random peptide libraries displayed on phage. Infect Immun. 1999;67(9):4679-88.
130. Prudencio CR, Marra AO, Cardoso R, Goulart LR. Recombinant peptides as new immunogens for the control of the bovine tick, Rhipicephalus (Boophilus) microplus. Vet Parasitol. 2010;172(1-2):122-31.
131. Tang LF, Yi XY, Zeng XF, Wang LQ, Zhang SK. Schistosoma japonicum: isolation and identification of peptides mimicking ferritin epitopes from phage display library. Acta Biochim Biophys Sin (Shanghai). 2004;36(3):206-10.
132. Wu HW, Hu XM, Wang Y, Kurtis JD, Zeng FJ, McGarvey ST, Wu GL, Zhang ZS, Hua ZC. Protective immunity induced by phage displayed mitochondrial related peptides of Schistosoma japonicum. Acta Trop. 2006;99(2-3):200-7.
133. Buchwald UK, Lees A, Steinitz M, Pirofski LA. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect Immun. 2005;73(1):325-33.
134. Feliciano ND, Ribeiro Vda S, Santos Fde A, Fujimura PT, Gonzaga HT, Goulart LR, Costa-Cruz JM. Bacteriophage-fused peptides for serodiagnosis of human strongyloidiasis. PLoS Negl Trop Dis. 2014;8(5):e2792.
135. Gonzalez E, Robles Y, Govezensky T, Bobes RJ, Gevorkian G, Manoutcharian K. Isolation of neurocysticercosis-related antigens from a genomic phage display library of Taenia solium. J Biomol Screen. 2010;15(10):1268-73.
136. Guo A, Cai X, Jia W, Liu B, Zhang S, Wang P, Yan H, Luo X. Mapping of Taenia solium TSOL18 antigenic epitopes by phage display library. Parasitol Res. 2010;106(5):1151-7.
137. Di Cristina M, Del Porto P, Buffolano W, Beghetto E, Spadoni A, Guglietta S, Piccolella E, Felici F, Gargano N. The Toxoplasma gondii bradyzoite antigens BAG1 and MAG1 induce early humoral and cell-mediated immune responses upon human infection. Microbes Infect. 2004;6(2):164-71.
138. Suo S, Wang X, Zarlenga D, Bu RE, Ren Y, Ren X. Phage display for identifying peptides that bind the spike protein of transmissible gastroenteritis virus and possess diagnostic potential. Virus Genes. 2015;51(1):51-6.
139. Lim PL, Tam FC, Chui YL, Ng LW. Identification of a surrogate TSL-1 antigen of Trichinella spiralis from a phage library of random peptides. Parasite Immunol. 1997;19(6):281-6.
140. Gu Y, Li J, Zhu X, Yang J, Li Q, Liu Z, Yu S, Li Y. Trichinella spiralis: characterization of phage-displayed specific epitopes and their protective immunity in BALB/c mice. Exp Parasitol. 2008;118(1):66-74.
141. Pitcovsky TA, Mucci J, Alvarez P, Leguizamon MS, Burrone O, Alzari PM, Campetella O. Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants. Infect Immun. 2001;69(3):1869-75.
142. Adey N, Stemmer P, Kay B. Preparation of second generation phage libraries. Chapter. 1996;16:277-91.
143. Thie H, Voedisch B, Dubel S, Hust M, Schirrmann T. Affinity maturation by phage display. Methods Mol Biol. 2009;525:309-22. xv.
144. Thie H. Affinity maturation by random mutagenesis and phage display. Antibody Engineering. 2010;409:397-409.
145. Dias-Neto E, Nunes DN, Giordano RJ, Sun J, Botz GH, Yang K, Setubal JC, Pasqualini R, Arap W. Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS One. 2009;4(12):e8338.
146. Liu GW, Livesay BR, Kacherovsky NA, Cieslewicz M, Lutz E, Waalkes A, Jensen MC, Salipante SJ, Pun SH. Efficient Identification of Murine M2 Macrophage Peptide Targeting Ligands by Phage Display and Next-Generation Sequencing. Bioconjug Chem. 2015;26(8):1811-7.
147. Matochko WL, Cory Li S, Tang SK, Derda R. Prospective identification of parasitic sequences in phage display screens. Nucleic Acids Res. 2014;42(3):1784-98.
148. Menendez A, Scott JK. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal Biochem. 2005;336(2):145-57.
149. t Hoen PA, Jirka SM, Ten Broeke BR, Schultes EA, Aguilera B, Pang KH, Heemskerk H, Aartsma-Rus A, van Ommen GJ, den Dunnen JT. Phage display screening without repetitious selection rounds. Anal Biochem. 2012;421(2):622-31.